A Phase Ib Study of Pembrolizumab in Bladder Cancer

Article
Conference|ESMO Congress

Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.

Clinical Pearls

Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.

  • 33 patients with urothelial tract cancer were enrolled on this trial.
  • A subset of patients experienced a decrease in tumor volume. There were 3 complete responses.
  • Overall survival data seen in this study were at the top bound of historical data.

<<<

View more from the 2014 ESMO Congress

Recent Videos
Related Content
Trial of Paxalisib With Immunotherapy in Advanced Breast Cancer Begins

Trial of Paxalisib With Immunotherapy in Advanced Breast Cancer Begins

Jordyn Sava
February 6th 2025
Article

This approach aims to improve treatment for patients with this highly aggressive and treatment-resistant type of breast cancer.

Read More

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Jordyn Sava;Yu Fujiwara, MD
August 1st 2024
Podcast

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Listen

Bevacizumab Benefits in CRC Persist for Two Years After Initiation

Bevacizumab Benefits in CRC Persist for Two Years After Initiation

Darlene Dobkowski, MA
February 1st 2025
Article

Bevacizumab's survival benefits in CRC patients persist for about 2 years after starting treatment.

Read More

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Jordyn Sava;Aaron Lisberg, MD
December 15th 2023
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Listen

Watch and Wait Post-TNT Safe with Similar Outcomes to TME in Rectal Cancer

Watch and Wait Post-TNT Safe with Similar Outcomes to TME in Rectal Cancer

Roman Fabbricatore
January 31st 2025
Article

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage II/III rectal cancer.

Read More

Early Palliative Care Improves EOL Comfort in Colorectal Cancer

Early Palliative Care Improves EOL Comfort in Colorectal Cancer

Roman Fabbricatore
January 30th 2025
Article

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

Read More